Evaluating PSA dynamics for predicting androgen deprivation failure with a patient specific prostate cancer model.
1/5 보강
Prostate cancer is the second leading cause of cancer-related death among American men, with a new diagnosis made every 2 min in the United States.
APA
Zhao S, Keller ET, et al. (2025). Evaluating PSA dynamics for predicting androgen deprivation failure with a patient specific prostate cancer model.. NPJ systems biology and applications, 11(1), 59. https://doi.org/10.1038/s41540-025-00540-y
MLA
Zhao S, et al.. "Evaluating PSA dynamics for predicting androgen deprivation failure with a patient specific prostate cancer model.." NPJ systems biology and applications, vol. 11, no. 1, 2025, pp. 59.
PMID
40456781
Abstract
Prostate cancer is the second leading cause of cancer-related death among American men, with a new diagnosis made every 2 min in the United States. Advanced cases are commonly treated with androgen deprivation therapy (ADT). Despite its effectiveness, treatment failure remains inevitable for many patients, necessitating better predictive tools for clinical management of disease. This study presents a data-driven mathematical modeling approach that integrates patient-specific prostate-specific antigen (PSA) time-course data with experimentally measured PSA expression rates to improve the prediction of ADT failure. Our findings suggest that post-nadir PSA dynamics, rather than initial decline, hold greater prognostic value and can inform PSA monitoring schedules. By employing virtual clones of individual patients, our model integrates routinely collected PSA measurements to dynamically predict ADT failure probabilities at future clinic visits. If implemented in clinical practice, this personalized framework could empower oncologists to make proactive, informed treatment decisions and guide timely interventions.
MeSH Terms
Male; Humans; Prostatic Neoplasms; Prostate-Specific Antigen; Androgen Antagonists; Treatment Failure; Prognosis
같은 제1저자의 인용 많은 논문 (5)
- Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.
- Vitamin D in synergy with triple therapy to eradicate Helicobacter pylori infection in mice via the c-Raf/MEK/ERK pathway.
- A novel bicyclic peptide-drug conjugate of 3-fluoro-10-hydroxy-evodiamine for targeted colorectal cancer therapy.
- DNA Logic Gate-Integrated Peptide Nucleic Acid-Optical Fiber Sensor for Ultrasensitive Breast Cancer Exosome Profiling.
- Anatomy-guided visual prompt tuning for cross-modal breast cancer understanding.